Literature DB >> 31225898

Fractional CO2 Laser Treatment Outcomes for Pediatric Hypertrophic Burn Scars.

Sagar P Patel1, Ha Vi Nguyen1, Diana Mannschreck1, Richard J Redett2, Katherine B Puttgen1, F Dylan Stewart3.   

Abstract

Carbon dioxide ablative fractional laser (CO2-AFL) therapy has not been widely adopted in pediatric burn care given limited outcomes literature and no established guidelines on laser treatment protocols. We present our experience to further elucidate the clinical role of CO2-AFL therapy for pediatric hypertrophic burn scars. We conducted a prospective cohort study of pediatric burn patients undergoing CO2-AFL treatment of hypertrophic, symptomatic burn scars at a tertiary care regional burn center during a 2-year period. Scars were assessed before each treatment using the Patient and Observer Scar Assessment Scale (POSAS), a validated, subjective, comprehensive scar assessment tool. We treated 49 pediatric patients for a total of 180 laser sessions. Burn severity was full thickness (63.6%) or deep partial thickness (47.7%). Observer-rated POSAS scores revealed statistically significant improvements in pigment, thickness, relief, pliability, and surface area after one treatment with continued improvement until the last laser session. Patient-rated POSAS revealed statistically significant improvements in color, stiffness, thickness, and irregularity after laser treatments. Total POSAS improved from 89.6 ± 17.5 to 76.6 ± 16.8 (P < .0001) after one treatment with further improvement to 69.2 ± 14.9 (P < .0001) at the final laser session. We found convincing evidence that CO2-AFL therapy improves hypertrophic burn scars on both patient- and observer-rated scales confirming statistical and clinical significance to both providers and families. These findings demonstrate that CO2-AFL can improve hypertrophic burn scars in pediatric patients providing a lower risk alternative to invasive therapies and a more immediate, efficacious alternative to more conservative scar treatments. © American Burn Association 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Year:  2019        PMID: 31225898     DOI: 10.1093/jbcr/irz046

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  7 in total

Review 1.  Use of Biologic Agents for Lip and Cheek Reconstruction.

Authors:  Monal Depani; Andrew M Ferry; Andrew E Grush; Tanir A Moreno; Lloyd M Jones; James F Thornton
Journal:  Semin Plast Surg       Date:  2021-12-31       Impact factor: 2.195

Review 2.  Scar Revisions.

Authors:  Anna Skochdopole; Rami P Dibbs; Shayan M Sarrami; Robert F Dempsey
Journal:  Semin Plast Surg       Date:  2021-06-08       Impact factor: 2.314

3.  Effects of multiple modes of UltraPulse fractional CO2 laser treatment on extensive scarring: a retrospective study.

Authors:  Xiaojing Ge; Yute Sun; Jing Lin; Fang Zhou; Gang Yao; Xin Su
Journal:  Lasers Med Sci       Date:  2021-08-26       Impact factor: 3.161

4.  Extragenital Bullous Lichen Sclerosus Treated with Fractional CO2 Laser (FxCO2) and Wet Dressing of Halcinonide Solution: A Case Report.

Authors:  Yunyan Yuan; Caroline J Wang; Houmin Li
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-03-10

5.  A six-herb Chinese medicine composition ointment as a promising candidate for treatment of hypertrophic scars.

Authors:  Zu-Hua Wang; Xue-Yan Sun; Jiao-Jiao Zhang; Francesca Giampieri; Cheng-Ju Jiang; Ting-Ting Feng; Zhi-Wei Wang; Rong-Yi Chen; Maurizio Battino; Ying Zhou
Journal:  Chin Herb Med       Date:  2020-12-29

Review 6.  Avoidance and Correction of Deformities in Body Contouring.

Authors:  Andrew M Ferry; Edward Chamata; Rami P Dibbs; Norman H Rappaport
Journal:  Semin Plast Surg       Date:  2021-06-08       Impact factor: 2.314

7.  Application effect of lattice laser in facial rejuvenation: A protocol for systematic review and meta-analysis.

Authors:  Dan Yan; Zechun Huang; Anli Zhang; Shuaihua Li; Yao Xiao
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.